---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-001957"
form_type: "8-K"
ticker: "BICX"
cik: "0001443863"
company_name: "BioCorRx Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:49:53.405488+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCorRx acquires additional 12.15% of subsidiary via stock-for-stock exchange with insiders

## Summary
- Entered stock exchange agreement with CEO, President, and board member to transfer 1,215 subsidiary shares for 2,263,371 parent shares.
- Exchange closed March 27, 2026; intended as tax-free reorganization under Section 368(a)(1)(B).
- Subsidiary BioCorRx Pharmaceuticals was ~12.15% minority stake acquired; no cash consideration paid.
- Parent shares are unregistered, issued under Section 4(a)(2) exemption; registration rights granted to shareholders.
- Part of Plan of Reorganization to obtain control of subsidiary under Section 368(c) of the Code.

## SEC filing metadata
- accession: 0001477932-26-001957
- form_type: 8-K
- ticker: BICX
- cik: 0001443863
- company_name: BioCorRx Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1443863/000147793226001957/0001477932-26-001957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1443863/000147793226001957/bicx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-001957
- JSON: https://secwatch.observer/filing/0001477932-26-001957.json
- Plain text: https://secwatch.observer/filing/0001477932-26-001957.txt

## Source-grounded claims
- claim_id: ff50b2324c0c9c2ca3f2c0f396104f963c43ae6a
  claim: BioCorRx Inc. entered into Agreement with Lourdes Felix, Louis C Lucido, and Kent Emry (effective 2026-03-26).
  evidence_excerpt: On March 26, 2026, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a stock exchange agreement (the “Agreement”) with Lourdes Felix, Chief Executive Officer of the Company and a member of the Company’s Board of Directors (the “Board”), Louis C Lucido, President of the Company and a member of the Board, and Kent Emry (collectively with Lourdes Felix and Louis C Lucido, the “Shareholders”), a member of the Board, pursuant to which the Shareholders agreed to transfer to the Company an aggregate of 1,215 shares of common stock of BioCorRx Pharmaceuticals, Inc., a Nevada corporation, which is a majority-owned subsidiary of the Company (the “Subsidiary”), representing in the aggregate approximately 12.15% of the outstanding common stock of the Subsidiary, in exchange for an aggregate of 2,263,371 shares (the “Parent Shares”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1443863/000147793226001957/0001477932-26-001957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.